Listen

STAT Plus: How does Biogen move beyond its Alzheimer’s drug blowup? Listen for the clues

[ad_1] When Biogen (BIIB) reports first-quarter earnings on Wednesday morning, investors will be listening for what, if anything, management says about the biotech’s path forward in the wake of its...

Read more
Listen: Democratizing CRISPR, drugging the undruggable, and reading pharma’s fine print

[ad_1] Who gets to “play God”? Can old technologies learn new tricks? And what does “drug price” even mean? We discuss all that and more on the latest episode of...

Read more
Listen: Trump’s drug pricing foot soldier, Gilead’s uncertain future, & transpacific angst

[ad_1] How do you sell lefty ideas to righty politicians? What’s going on at Gilead Sciences? And why are biotech investors freaking out? We discuss all that and more on...

Read more
Listen: Cheaper insulin, the next Juul, and diagnosing disease with sound

[ad_1] What if pharma just charged less for drugs? Can speaking three syllables reveal whether you’re depressed? And why is Snoop Dogg selling erectile dysfunction pills on TV? We discuss...

Read more
Listen: How startups stop, the new FDA boss, and Theranos on the big screen

[ad_1] Who deserves credit for a new gene therapy? How do you push stop on a startup? And what does MC Hammer have to do with Theranos? We discuss all...

Read more
Listen: Every conceivable angle of Scott Gottlieb’s FDA resignation

[ad_1] Why is Scott Gottlieb quitting the FDA? Who will replace him? And what’s the proper elastane content of a skinny jean? We discuss all that and more on the...

Read more
P002 WHEN THE PATIENT VOICE IS HEARD IN EDUCATION, DOES THE CLINICIAN LISTEN? DUAL TRACK PATIENT/PROVIDER EDUCATION IN IBD INCORPORATING PATIENTS AS LEARNERS AND FACULTY

[ad_1] It is postulated that patient inclusion in planning/execution of continuing medical education (CME) activities may better engage providers, reinforce learning, and improve outcomes. RMEI Medical Education’s (RMEI’s) proprietary Clinical...

Read more
Want to integrate care? Listen to the patient

[ad_1] Integrated care and interoperability is complex if it has to be managed by experts. It becomes pretty easy once you let the patient have a say, according to Philipp...

Read more
Listen: CEOs at the Senate, merger mania, and sleuthing startups

[ad_1] Is this the age of the big biotech buyout? Is cold brew a business expense? And how do you pronounce “Gonzalez”? We discuss all that and more on the...

Read more
LISTEN: A big scoop on opioid marketing

[ad_1] What did an opioid patriarch say under oath? Why did everyone want to know so badly? And how might it shape the conversation around the opioid crisis? We discuss...

Read more
LISTEN: Painkiller racketeering, the limits of genetic tests, and pharma’s day on the Hill

[ad_1] Is pharma about to have its Big Tobacco moment? Are we overestimating human genetics? And can sales reps rap? We discuss all that and more on the latest episode...

Read more
LISTEN: The AI hype machine, ketamine’s future, and the rocky path ahead for NASH

[ad_1] When will AI replace your radiologist? What can pharma learn from ketamine? And is liver disease more complicated than anyone thought? We discuss all that and more on the...

Read more
LISTEN: A bad day for bold biotech, campaign 2020, and where do drugs come from?

[ad_1] Are we underestimating biology? Will Hot 97 decide the presidency? And who owns the scientific means of production? We discuss all that and more on the latest episode of...

Read more
LISTEN: Another Alzheimer’s setback, crypto for biotech, and a blessing of unicorns

[ad_1] Is the drug industry wrong about Alzheimer’s disease? Can cryptocurrency fund actual science? And should you feel sorry for Big Pharma? We discuss all that and more on the...

Read more
What to Listen for & Ask at Your Tummy Tuck Consultation

[ad_1] Your tummy tuck consultation is one of the most important steps before your actual procedure. Take your time when choosing a plastic surgeon or two with whom to schedule...

Read more
LISTEN: CRISPR upheaval, Celgene’s chutzpah, and canine genomics

[ad_1] Is genome editing harder than anyone thought? Will no one weep for Celgene? And is it time to sequence your dog? We discuss all that and more on the...

Read more
LISTEN: FDA furloughs, ’80s pop radio, and video game therapeutics

[ad_1] Is the FDA going broke? Can video games be drugs? And when did “Flashdance” come out? We discuss all that and more on the latest episode of “The Readout...

Read more
LISTEN: A people’s history of J.P. Morgan

[ad_1] Do drug developers tip well? Is biotech safe for 6-year-olds? And what’s a Cable Car Cosmo? We discuss all that and more on this week’s episode of “The Readout LOUD,”...

Read more
LISTEN: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring

[ad_1] Are megamergers bad for business? Is it time for biotech’s biggest gathering to find a new home? And can a “need” be anything but “unmet”? We discuss all that...

Read more
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

[ad_1] NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chief Operating Officer, and Mikael Dolsten, President, Worldwide...

Read more